Accelerate to Discover

Back to filter

Related topics

NovoCyte Quanteon - when exceptional performance meets simplicity

Acea Biosciences

Jun 21, 2018

NovoCyte Quanteon system is the answer for growing demands in modern flow-cytometry assays. With its four lasers (405,...

Real-time study of platelet formation under sheer-flow with Lumascope

Etaluma

Jun 18, 2018

Platelet formation was observed with Lumascope microscope in a uniform-sheer-flow biorector. Videos of the formation...

Early fetal sex determination using micro-volume of maternal plasma

BJS Biotechnologies

Jun 16, 2018

 A qPCR-based assay, SneakPeek Early Gender Test (Gateway Genomics) has been developed to determine fetal sex as early...

3R Compliant drug development studies

Bruker Biospin

Jun 8, 2018

In preclinical imaging, magnetic resonance imaging (MRI) can be an attractive alternative to researchers who have...

Jun 21, 2018

Kinase study of cytotoxicity voted paper of the year.

Acea Biosciences

Jun 6, 2018

Society of Toxicology voted a xCELLigence based paper the Paper of the Year. The study of cytotoxicity was done using...

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Acea Biosciences

Jun 4, 2018

Search for dual action drugs against both HIV and Tuberculosis has lead to the creation of heterodimeric compounds with...

Mutual destruction of deep Lung tumor tissues by nanodrug‐conjugated and CQ1 imaging cytometer

Yokogawa

Jun 1, 2018

Lung cancer is a highly malignant tumor, and targeted delivery of anti‐cancer drugs to deep lung tumor tissue remains a...

Jun 21, 2018

Method to quantify local force distribution within biomolecular systems

LUMICKS

May 24, 2018

The journal Nano Letters has recently published the article “Quantifying Local Molecular Tension Using Intercalated DNA...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, Label Free Cell Analysis

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey